CANCER VACCINE PROVENGE: Dendreon Shares Rise On Drug Study Results

CANCER VACCINE PROVENGE: Dendreon Shares Rise On Drug Study Results

Dendreon Inc. shares surged Wednesday as investors lauded the detailed study results for the drug developer's prostate cancer

The stock doubled in value to $24.57 in afternoon trading, a day after seesawing in anticipation of details on a late-stage clinical trial for Provenge. Earlier in April, the company reported that Provenge met its goal of prolonging the survival of men with prostate cancer.

Popular in the Community

Close

What's Hot